Neurodegenerative diseases involve highly complex and interconnected pathogenic mechanisms, where single-target agents have repeatedly failed to deliver meaningful clinical outcomes. AevisBio is developing novel therapies for neurodegenerative diseases through synthetic neuroprotection — a dual strategy that suppresses neuroinflammation via ZFP91 degradation and prevents toxic α-synuclein aggregation. This innovative approach aims to overcome the limitations of single-target agents in complex brain disorders.

Neurodegenerative diseases involve highly complex and interconnected pathogenic mechanisms, where single-target agents have repeatedly failed to deliver meaningful clinical outcomes. AevisBio is developing novel therapies for neurodegenerative diseases through synthetic neuroprotection — a dual strategy that suppresses neuroinflammation via ZFP91 degradation and prevents toxic α-synuclein aggregation. This innovative approach aims to overcome the limitations of single-target agents in complex brain disorders.

At the core of AevisBio’s innovation is our Molecular Glue discovery platform, built on proprietary Cereblon-Binding Modules (CBMs) and a Proteomics-based Degron Library (PDL). This platform systematically identifies and optimizes novel degraders, expanding drug discovery into previously unreachable targets.